

16
#8

SCULLY, SCOTT, MURPHY & PRESSER
400 GARDEN CITY PLAZA
GARDEN CITY, NEW YORK 11530

Telephone: (516) 742-4343
Facsimile: (516) 742-4366
E-Mail: intprop@ssmp.com

RECEIVED

JUN 13 2002

FACSIMILE TRANSMISSION

TECH CENTER 1600/2900

To: U. S. Patent and Trademark Office Attention: Corrected Filing Receipt
Date: May 2, 2002
Fax #: 703-308-7751 Pages 3
From: SCULLY, SCOTT, MURPHY & PRESSER

Re: Joachim Hauber, et al.
U.S. Patent Appln. No. 10/025,367
COMPOUNDS THAT AFFECT CD83 EXPRESSION,
PHARMACEUTICAL COMPOSITIONS COMPRISING
SAID COMPOUNDS AND METHODS FOR
IDENTIFYING SAID COMPOUNDS
Our Docket: 15120

COMMENTS:

The Filing Receipt for the above-identified patent application has incorrect information in the Foreign Applications.

It should read as follows:

FOREIGN APPLICATIONS: GREAT BRITAIN 0031145.6 12/20/2000

Please send to us a corrected Filing Receipt with the information as it is shown on the pages to follow.

Thank you.

If there are any problems concerning this facsimile, please call (516) 742-4343 and ask for Rosemarie at Ext.596

CONFIDENTIALITY: The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right of publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.

DECLARATION FOR PATENT APPLICATION

As a below named inventor, we hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled COMPOUNDS THAT AFFECT CD81 EXPRESSION PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS, the specification of which is attached hereto unless the following box is checked:

☒ was filed on December 19, 2001 as United States Application Number or PCT International Application Number _____ and was Amended on _____ (if application).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

0031145.6 Great Britain December 20, 2000
(Number) (Country) (Day/Month/Year Filed)

Priority Not Claimed

☐☐

(Number) (Country) (Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Number) (Filing Date)

(Application Number) (Filing Date)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application Number) (Filing Date) (Status—patented, pending, abandoned)

(Application Number) (Filing Date) (Status—patented, pending, abandoned)

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Stephen D. Murphy, Reg. No. 22,002; Leopold Presser, Reg. No. 19,827; William C. Roch, Reg. No. 24,972; Kenneth L. King, Reg. No. 24,223; Frank S. DiGiglio, Reg. No. 31,346; Paul J. Esatto, Jr., Reg. No. 30,749; John S. Sensy, Reg. No. 28,757; Mark J. Cohen, Reg. No. 32,211; Richard L. Catania, Reg. No. 32,608; and Edward W. Grolz, Reg. No. 33,705.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/025,367	12/19/2001	1645	956	15120	15	32	3

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530

RECEIVED FILING RECEIPT

JUN 13 2002



0000000007650590

TECH CENTER 1600/2900

Date Mailed: 03/18/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Joachim Hauber, Residence Not Provided;
Alexander Thorsten Prechtel, Residence Not Provided;

Domestic Priority data as claimed by applicant

Foreign Applications

UNITED KINGDOM 003445.6 12/20/2000

If Required, Foreign Filing License Granted 03/15/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds

Preliminary Class

435

Should Read:
Great Britain
0031145.6
12/20/2000